UK: Divestment Astra Zeneca Successfully Completes Agreement with Atnahs Pharma
Astra Zeneca has received 350 million dollars from Atnahs and the deal includes divestment of the former’s global commercial rights for Inderal, Tenormin, Tenoretic, Zestril and Zestoreticm, which are established hypertension medicines.
Cambridge/United Kingdom – Astra Zeneca recently announced that it has completed the previously communicated agreement with Atnahs Pharma (Atnahs) to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).
Under the terms of the agreement, Astra Zeneca has received a payment of 350 million dollars from Atnahs. The company may also receive future sales-contingent payments of up to 40 million dollars between 2020 and 2022. The upfront payment will be reported in Astra Zeneca’s financial statements within Other Operating Income & Expense in the first quarter of 2020.
Inderal (propranolol) is a beta-blocker and is predominantly used to treat tremors, angina, hypertension, arrhythmias, and other heart or circulatory conditions. It is also used to reduce the severity and frequency of migraine.
Tenormin and Tenoretic
Tenormin (atenolol) is a beta-blocker that is used to treat angina and hypertension, as well as certain kinds of arrhythmias. It is also used to lower the risk of death after a heart attack. Tenoretic is a fixed-dose combination of atenolol (beta-blocker) and chlorthalidone (diuretic), used to treat high blood pressure.
Zestril and Zestoretic
Zestril (lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension, congestive heart failure, diabetic-related conditions and hypertensive renal disease. Zestril may also be used to improve survival after a heart attack. Zestoretic is a fixed-dose combination of lisinopril (ACE inhibitor) and hydrochlorothiazide (diuretic) used to treat hypertension.